Scholarlink

Objectives <p>Since the efficacy of salvage photodynamic therapy (PDT) for locally recurrent esophageal cancer after definitive chemoradiotherapy (CRT) was proven for the first time in an investigator-initiated clinical trial, various reports have supported the clinical utility of PDT for these lesions. However, the clinical trial had limited indications, including a luminal circumference of ≤1/2, maximum longitudinal lesion length of 3 cm, and no invasion into the cervical esophagus, and there have been few reports of treatment outcomes for lesions exceeding the indications used in the investigator-initiated clinical trial. Therefore, this study was performed to assess the outcomes of treating lesions exceeding the above indications.</p> Methods <p>We retrospectively enrolled 34 consecutive esophageal cancer patients with 38 lesions who underwent PDT with talaporfin sodium. Lesions were classified as meeting (within-indications group; 23 patients, 25 lesions) or exceeding (beyond-indications group; 11 patients, 13 lesions) the indications in the investigator-initiated clinical trial. The local complete response rate (L-CR), overall survival (OS), progression-free survival (PFS), and incidence of PDT-related adverse events were compared between the groups.</p> Results <p>The L-CR rate was 88.0 and 92.3% in the within- and beyond-indications groups, respectively. The 2-year OS rate was 69.5% and 90.0% and the 2-year PFS rate was 43.3 and 56.6% in the within- and beyond-indications groups, respectively. In terms of adverse events, there were no serious adverse events in either group.</p> Conclusion <p>Salvage PDT might be effective for local recurrence after CRT for lesions exceeding the indications in the investigator-initiated clinical trial.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the efficacy and safety of salvage photodynamic therapy with talaporfin sodium for lesions beyond those indicated for investigator-initiated clinical trials

  • 期刊论文

  • 发表日期：

    2025年6月15日

查看全文
  • Nobuhito Ito,
  • Kohei Funasaka,
  • Kazuhiro Furukawa,
  • Kazuki Nishida,
  • Satoshi Furune,
  • Takashi Hirose,
  • Takahiro Suzuki,
  • Emiko Hida,
  • Keiko Hirai,
  • Hiroyuki Shibata,
  • Yoshiyuki Kurata,
  • Hitoshi Tanaka,
  • Takeshi Yamamura,
  • Takuya Ishikawa,
  • Masanao Nakamura,
  • Ryoji Miyahara,
  • Hiroki Kawashima

摘要

Objectives

Since the efficacy of salvage photodynamic therapy (PDT) for locally recurrent esophageal cancer after definitive chemoradiotherapy (CRT) was proven for the first time in an investigator-initiated clinical trial, various reports have supported the clinical utility of PDT for these lesions. However, the clinical trial had limited indications, including a luminal circumference of ≤1/2, maximum longitudinal lesion length of 3 cm, and no invasion into the cervical esophagus, and there have been few reports of treatment outcomes for lesions exceeding the indications used in the investigator-initiated clinical trial. Therefore, this study was performed to assess the outcomes of treating lesions exceeding the above indications.

Methods

We retrospectively enrolled 34 consecutive esophageal cancer patients with 38 lesions who underwent PDT with talaporfin sodium. Lesions were classified as meeting (within-indications group; 23 patients, 25 lesions) or exceeding (beyond-indications group; 11 patients, 13 lesions) the indications in the investigator-initiated clinical trial. The local complete response rate (L-CR), overall survival (OS), progression-free survival (PFS), and incidence of PDT-related adverse events were compared between the groups.

Results

The L-CR rate was 88.0 and 92.3% in the within- and beyond-indications groups, respectively. The 2-year OS rate was 69.5% and 90.0% and the 2-year PFS rate was 43.3 and 56.6% in the within- and beyond-indications groups, respectively. In terms of adverse events, there were no serious adverse events in either group.

Conclusion

Salvage PDT might be effective for local recurrence after CRT for lesions exceeding the indications in the investigator-initiated clinical trial.